Synergistic Remodeling of Tumor Immune Microenvironment via a DNA Nanodevice Integrating STING Activation and Lysosome-Targeted PD-L1 Degradation.

Haoxiang Li, Min Hou, Shasha Sun, Jun Cao, Jian-Hui Jiang, Jianjun He

Abstract read

In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Haoxiang LiSchool of Biomedical Sciences, State Key Laboratory of Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha, China.

Min HouSchool of Physics and Chemistry, Hunan First Normal University, Changsha, China.

Shasha SunSchool of Biomedical Sciences, State Key Laboratory of Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha, China.

Jun CaoSchool of Biomedical Sciences, State Key Laboratory of Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha, China.

Jian-Hui JiangSchool of Biomedical Sciences, State Key Laboratory of Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha, China.ORCID https://orcid.org/0000-0003-1594-4023

Jianjun HeSchool of Biomedical Sciences, State Key Laboratory of Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha, China.ORCID https://orcid.org/0000-0001-9779-2662

Funding

Key Fundamental Research Program Hunan Province 2025JC0003Science and Technology Innovation Program of Hunan Province 2024RC3085Scientific Research Program of FuRong Laboratory 2025PT5030

6 · The paper itself

Abstract

The cGAS-STING pathway is a cornerstone of innate antitumor immunity; however, its therapeutic potential is often limited by the inefficient cytosolic delivery of agonists and the immunosuppressive tumor microenvironment (TME). Here, we report a DNA nanostructure-based platform that simultaneously induces lysosomal degradation of immune checkpoint protein PD-L1 and activates the STING pathway. We demonstrate that STING activation further enhances PD-L1 degradation, resulting in strong synergistic immune activation. In murine models of triple-negative breast cancer, the DNA nanodevice effectively reprograms the TME by enhancing dendritic cell maturation and CD8

Indexed as

B7-H1 AntigenLysosomesMembrane ProteinsTriple Negative Breast NeoplasmsTumor MicroenvironmentAnimalsCell Line, TumorcGAS-STING Signaling PathwayDendritic CellsDNA NanostructuresFemaleHumansImmunotherapyMiceSTING ProteinB7-H1 AntigenMembrane ProteinsSTING1 protein, humanSting1 protein, mouseSTING ProteinCGAS‐STINGimmunotherapytargeted protein degradationtumor microenvironmenttumor treatment

Identifiers

PMID42201604

DOI10.1002/advs.75855

PMCPMC13336052

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.